ArticleCurrent infectious disease reports2001
What's New in beta-lactamases?
Article in Current infectious disease reports, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Role of a mutation at position 167 of CTX-M-19 in ceftazidime hydrolysis.Antimicrobial agents and chemotherapy · 2004Article
- Occurrence of newer beta-lactamases in Klebsiella pneumoniae isolates from 24 U.S. hospitals.Antimicrobial agents and chemotherapy · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
beta-lactamases continue to be the leading cause of resistance to beta-lactam antibiotics, among gram-negative bacteria. In recent years, both the incidence and the prevalence of extended-spectrum beta-lactamases, inhibitor-resistant beta-lactamases, AmpC-type enzymes, and both metallo- carbapenemases and nonmetallo-carbapenemases have increased. These beta-lactamases provide resistance to oximino-cephalosporins, beta-lactam/beta-lactamase inhibitor combinations, cephamycins, and carbapenems, respectively. Strains expressing these beta-lactamases will generate a host of therapeutic challenges as we begin the 21st century.
Identifiers
11177726What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.